Answers are grounded in this paper and cite their sources.
Denosumab, a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, is widely used to treat osteoporosis. Its role as a trigger for autoimmune hepatitis (AIH) remains uncertain. We report a 68-year-old woman with osteoporosis and Hashimoto thyroiditis who developed jaundice and severe hepatocellular liver injury after 3 years of denosumab therapy. Alternative viral, obstructive, and metabolic causes were excluded. Liver biopsy demonstrated interface hepatitis with a lymphoplasmacytic portal infiltrate consistent with AIH, and autoimmune serologies were positive. Hemophagocytic lymphohistiocytosis was excluded, and an International AIH Score of 17 supported a diagnosis of definite AIH. Treatment with corticosteroid-based immunosuppression resulted in complete biochemical remission, and denosumab was discontinued with transition to zoledronic acid to prevent rebound bone loss. Whether this case represents drug-induced autoimmune-like hepatitis or de novo idiopathic AIH occurring in a susceptible individual cannot be determined definitively. Clinicians should maintain a low threshold for evaluating liver injury in patients receiving denosumab who develop jaundice or marked transaminase elevation.
No takes yet. Share an insight, caveat, or question.
Maniattu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: